INSTI-based therapy for adults with an HIV viral load more than 500 000 RNA copies/mL

For single-tablet INSTI-based initial antiretroviral therapy in adults with an HIV viral load of more than 500 000 RNA copies/mL, use1:

1tenofovir alafenamide+emtricitabine+bictegravir (Biktarvy) 25 mg+200 mg+50 mg orally, daily. For dosage adjustment in adults with kidney impairment, see tenofovir alafenamide+emtricitabine+bictegravir dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy tenofovir alafenamide + emtricitabine + bictegravir (Biktarvy) tenofovir alafenamide+emtricitabine+bictegravir (Biktarvy) tenofovir alafenamide+emtricitabine+bictegravir (Biktarvy)

OR

1tenofovir alafenamide+emtricitabine+elvitegravir+cobicistat (Genvoya) 10 mg+200 mg+150 mg+150 mg orally, daily. For dosage adjustment in adults with kidney impairment, see tenofovir alafenamide+emtricitabine+elvitegravir+cobicistat dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat (Genvoya) tenofovir alafenamide+emtricitabine+elvitegravir+cobicistat (Genvoya) tenofovir alafenamide+emtricitabine+elvitegravir+cobicistat (Genvoya)

OR

1dolutegravir+abacavir+lamivudine (Triumeq) 50 mg+600 mg+300 mg orally, daily. For dosage adjustment in adults with kidney impairment, see dolutegravir+abacavir+lamivudine dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy2. dolutegravir + abacavir + lamivudine (triumeq) dolutegravir+abacavir+lamivudine (Triumeq) dolutegravir+abacavir+lamivudine (Triumeq)

1 Brand names are examples only; other brands may be available.Return
2 Test for HLA-B*5701 allele before prescribing abacavir – see Practice points for initial antiretroviral therapy.Return